Purpose To investigate if the ordinary use of a vaginal suppository containing miconazole results in systemic absorption that is sufficient to affect the activities of CYP1A2 and CYP3A4, which are major drug-and steroid-metabolising enzymes. Methods In 20 healthy non-pregnant women aged 18-45 years, the serum concentration of miconazole was determined following the use of a vaginal suppository containing 1,200 mg miconazole. Enzyme activities of CYP1A2 and CYP3A4 were determined as metabolic ratios of caffeine (CMR=(AFMU+1MU+1MX)/17DMU) and quinidine (QMR=3-hydroxy-quinidine/quinidine) respectively before and 34 h after insertion of the suppository. Miconazole was analysed by LC-MS/MS, while caffeine and metabolites were analysed by HPLC-UV and quinidine and hydroxy-quinidine were analysed by HPLC fluorescence. Results All 20 women had measurable concentrations of miconazole in serum (mean ± SD: 12.9±5.6 μg/L; range: 3.5-24.6 μg/L). Although not statistically significant, an association between the serum concentrations of miconazole and the inhibition of CYP1A2 activity was indicated. No relation was observed between the CYP3A4 activity and the miconazole serum concentration. Conclusions Miconazole is absorbed via the vaginal mucosa to the systemic circulation in measurable concentrations. Our data indicate a concentration-dependent inhibition of CYP1A2, but the effect is negligible compared with the variation in the activity of CYP1A2 and is regarded to be of no clinical significance to the women. However, further studies on the ability of miconazole to be transferred across the placenta or to interfere with the placental function are warranted to secure safe use during pregnancy.
Introduction
Miconazole (Fig. 1) is a pharmaceutical antifungal. It inhibits the fungal enzyme lanosterol 14-α-demethylase (CYP51), which regulates ergosterol synthesis essential for formation of the fungal cell membrane. Miconazole is used for the treatment of oral candidiasis in infants and vaginal mycoses in pregnant women and may reach the systemic circulation of the child and fetus if it is able to cross the mucous membrane and the placental barrier. However, the systemic bioavailability of miconazole following absorption via the vagina and the gut were reported to be low, 1.4% and 27% respectively [1] [2] [3] , and orally and vaginally absorbed miconazole were eliminated with half-lives between 2 and 57 h [3] [4] [5] . Nevertheless, drug interactions between oral gel or vaginally used miconazole and the anticoagulant warfarin have been reported, indicating a systemic concentration high enough to affect biotransformation [6, 7] .
In a panel of in vitro test systems, miconazole showed the potential to disrupt the endocrine system by several mechanisms [8] . Miconazole inhibited testosterone biosynthesis and the estrogen synthesising enzyme aromatase (CYP19) and it was a weak estrogen receptor antagonist. In other experimental test systems, miconazole had unspecific effects on the humane cytochrome P450 (CYP) system and has been reported to inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP17, CYP19 and CYP51 activities [9] [10] [11] [12] [13] [14] . However, the inhibitory potency of miconazole differed among different CYPs. CYP17 and CYP19 are involved in steroid synthesis whereas CYP1A2 and CYP3A4 are major drug-metabolising enzymes, but they are also involved in estrogen metabolism [15, 16] . Disturbance of these enzymatic pathways may affect homeostasis. The developing fetal and infantile endocrine and reproductive systems are particularly susceptible to endocrine disrupting substances [17] [18] [19] . Other conazoles which like miconazole, have been reported to inhibit CYP19 and testosterone synthesis in vitro, and have been shown to disturb steroid synthesis in rat fetuses after prenatal exposure [20, 21] . Consequently, there is a concern that miconazole after ordinary use orally or in the vagina could result in systemic concentrations high enough to disturb the endocrine balance of the infant, the pregnant woman, or the fetus.
The primary aim of this study was therefore to investigate whether the ordinary use of a vaginal suppository containing 1,200 mg of miconazole resulted in systemic absorption. The secondary aim was then to investigate if the systemic concentration of miconazole was high enough to affect enzyme activities associated with CYP1A2 and CYP3A4.
Materials and methods

Subjects
Twenty healthy female subjects were recruited in the period May to August 2008. The participants were mainly students at the University of Southern Denmark or staff at Odense University Hospital. Characteristics of the study subjects are shown in Table 1 . After oral and written information about the study and their rights, 30 subjects gave their written consent and a written authority giving relevant personnel from the GCP Unit and the Danish Medicines Agency access to documents and data of importance for the study. Out of these 30, 4 subjects regretted their enrolment and withdrew their consent. Four individuals were excluded because of use of medication, and 2 were excluded since their electrocardiogram (ECG) revealed irregularities. Hence, 20 subjects completed the study.
Inclusion and exclusion criteria
Inclusion criteria were healthy, non-pregnant (evaluated by no detection of human chorionic gonadotrophin in a urine sample) and non-breastfeeding women aged between 18 and 45 years. They were ascertained to be in good health based on clinical examination including blood pressure, medical history and evaluation of a standard 12-lead ECG 
Study design and procedures
Initially, all participants answered a questionnaire regarding vegetable and fruit intake, smoking status, job function and use of antifungals in the homes including personal hygiene products such as shampoo or cream. For each subject the study lasted 11 days (Fig. 2) . It was a two-period study with a wash-out period of 2 days before each caffeine and quinidine administration period and of 5 days after insertion of the miconazole-containing vaginal suppository.
The subjects were asked to abstain from ingesting quinine-, quinidine-and methylxanthine-containing food and beverages (specific items were pointed out) as well as alcohol and medication, from 48 h before caffeine and quinidine administration and until the last blood sampling at day 8. To avoid pregnancy in the study period the subjects were asked to use a condom when having intercourse from the time of the pregnancy test until the insertion of the vaginal suppository. Thereafter, sexual abstinence was required until the end of the trial at day 11.
Each subject ingested 200 mg of caffeine (batch number 2151631) and 200 mg of quinidine (batch number 51313011), both supplied by the Central Pharmacy, Odense University Hospital (Denmark), at 11 pm on day 3. Previous studies indicate that simultaneous administrations of low doses of these two compounds do not influence the outcome of their respective metabolic ratios [22] [23] [24] . Morning urine was collected after a minimum of 3 h. Ten millilitres of the urine was poured into a conical tube containing 300 μl 1 M hydrochloric acid (HCl) for the CYP1A2 activity analysis. Forty millilitres was transferred into each of two sterile empty test tubes for the miconazole analysis. The urine samples were brought to the laboratory and stored at −20°C until analysis. At 9-10 h after quinidine administration, blood samples (5×10 ml) were collected by vein puncture at the laboratory for the CYP3A4 activity and miconazole analysis. Blood sampling was done by either the technician or the physician involved in the study. Twenty millilitres was collected in heparin tubes and 30 ml in dry tubes. All blood samples were centrifuged for 10 min at 3,500 rpm and plasma and serum were transferred to sterile cryogenic vials and kept frozen at -20°C until analysis.
On day 6 at 11 pm the vaginal suppository was inserted and the subjects were instructed to lie down afterwards for the night. Twenty-four hours later caffeine and quinidine were administered again for the evaluation of CYP1A2 and CYP3A4 activity after miconazole exposure. The urine and blood sampling procedures were repeated.
The time schedule was chosen based on knowledge from caffeine [25] and quinidine [23] kinetics studies and the findings of Daneshmend (1986) [3] , which showed a continuously maximal miconazole concentration in plasma from 6 to 48 h after insertion of a 1,200-mg miconazolecontaining suppository.
Determination of miconazole in serum
The serum concentration of miconazole was quantified by liquid chromatography coupled to a Thermo TSQ Quantum Ultra triple quadrupole mass spectrometer (LC-HESI-MS/MS system; Thermo Scientific, Waltham, MA, USA). The extraction procedure was as follows: a volume of 250 μl of the serum sample, 60 μl 0.2 M sodium hydroxide and 50 μl of internal standard (0.5 ng/ml tebuconazole in ethanol) was briefly vortex mixed in a 10-ml centrifugation tube. Then, 1 ml tert-butyl methylether was added and the samples were mixed horizontally for 20 min at 200 rpm followed by 15 min centrifugation at 3,000g. The supernatant was transferred to a new extraction tube. The extraction procedure was repeated. The two supernatants were combined and evaporated to accurate dryness at 40°C under a gentle stream of nitrogen. The dried extract was dissolved in 125 μl acetonitrile (ACN) followed by 125 μl buffer solution (2 mM ammonium acetate and 2 mM acetic acid, pH 4.6).
The sample was centrifuged for 10 min at 3,000 g, transferred to a 300-μl sample vial, and injected (30 μl) onto the analytical system. The separation was performed on a Phenomenex C12 MAX-RP column (4 μm, 150×2 mm) kept at 20°C using a two-solvent gradient system: (2 mM ammonium acetate and 2 mM acetic acid), pH 4.6 : ACN (95:5) (A) and (5:95) (B). The gradient profile was: 0 to 4.37 min: 40% to 100% B; 4.38 to 10.00 min: 100% B; 10.01 to 11.50 min: 100% to 40% B; 11.51 to 15.00 min: 40% B. The flow rate was 0.3 ml/min. The MS/MS system was operated with positive polarity in SRM mode with a scan width of 0.2 m/z and a scan time of 0.250 s. The spray voltage was 3,500 V, the vaporiser temperature 350°C, the sheath gas pressure 60 AU, the auxiliary gas pressure 45 AU and the capillary temperature 315°C. Miconazole was quantified with a parent mass of 416.86 m/z fragmented to a product mass of 160.95 m/z, and was detected at a retention time of 8.66 min. Tebuconazole was quantified with a parent mass of 308.1 m/z to the product masses of 124.8 and 70.0 m/z and was detected at a retention time of 5.91 min.
Quantitation of miconazole was based on calibration curves obtained after the addition of known concentrations of the compound to blank serum and water samples and then extracted and analysed as described above. The recovery of the extraction method was > 90%. The linearity was investigated in a range from 0.1 to 50.0 ng/ml (R 2 >0.98). The interday repeatability (n=3) was < 11 %. The accuracy for the quality control samples, spiked to a concentration of 5 ng/ml, was −4%. The limit of quantification (LOQ) for miconazole was 0.10 ng/ml and the limit of detection (LOD) was 0.05 ng/ml.
Determination of CYP1A2 activity
Four metabolites of caffeine: 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 1-methyluric acid (1MU), 1-methylxanthine (1MX) and 1,7-dimethyluric acid (17DMU) were determined in morning urine samples conserved with 1M HCl by high-performance liquid chromatography with UV detection [26] . The CYP1A2 activity was estimated by the caffeine metabolic ratio (CMR)=(AFMU+1MU+1MX)/17DMU.
Determination of CYP3A4 activity
Quinidine and 3-hydroxy-quinidine in plasma samples collected 9-10 h after ingestion of 200 mg quinidine were analysed using high-performance liquid chromatography, as described previously [27] . The CYP3A4 activity was estimated by the quinidine metabolic ratio (QMR)=3-hydroxy-quinidine/ quinidine as suggested by Damkier and Brosen [23] .
Data analysis
The mean miconazole absorption was tested by a paired t test comparing the mean miconazole concentrations in serum 34 h after and before the start of miconazole exposure. The differences in metabolic ratios are expressed as the relative differences, e.g. (CMR after -CMR before )/CMR before . The mean relative differences in CMR and QMR during and before exposure to miconazole were analysed by one-sample t tests comparing the relative differences with zero. The assumptions of normal distribution were considered fulfilled after evaluation by Q-Q plot (not shown) of the differences. The variations were roughly constant along the x-axis. Relative difference (Bland-Altman) plots of CMR and QMR were used as supplements to analyse the deviation between the metabolic ratios during and before exposure to miconazole.
The association between the relative difference in CMR or QMR and the miconazole concentration in serum was examined by linear regression. P values<0.05 were considered statistically significant. The statistical analyses were performed using Stata/SE 9.0 for Windows (Stata, College Station, TX, USA). Sample size calculations were based on the primary outcome, absorption of miconazole. As the background concentration of miconazole was zero and the LOQ=0.10 μg/L we consider a concentration of at least 1 μg/L to be an indication of absorption. Twenty women were considered suitable to detect miconazole in serum, which would give a power of >90% at a significance level of 5%.
Results
Subjects
None of the subjects had adverse drug reactions. Seventeen subjects had one or more side effects. The side effects that occurred were expected: headache, trouble sleeping, diar-rhoea, palpitations and vaginal itching/discomfort. All side effects were followed up and all subjects were well again after the study. Three subjects had no side effects.
Miconazole
The mean serum concentration of absorbed miconazole in the 20 women after 34 h use of a vaginal suppository containing 1,200 mg miconazole was 12.9±5.6 μg/L (mean ± SD; range: 3.5-24.6 μg/L; Fig. 3 ). Background serum concentrations of miconazole were below the limit of detection. The absorption of miconazole was not associated with menstruation during the study, age, or BMI (data not shown). The miconazole concentration in the urine samples was very high because of leakage from the vagina and therefore the urine concentration could not be used as an indication of the absorbed concentration of miconazole.
CYP1A2 and CYP3A4 activity
During the chromatographic detection of caffeine and metabolites, interference from the urine sample hindered the separation of AFMU in six samples. Consequently, only 14 out of 20 subjects were included in the calculations of CYP1A2 activity. One subject had trouble swallowing the quinidine capsule and therefore 19 out of 20 subjects were included in the CYP3A4 activity determination. The urine sampling time after caffeine administration differed between the two administrations with more than 1 h for 5 subjects, while for the rest of the subjects the difference was close to zero.
Data of CMR are presented as a scatter plot showing the relative difference in CMR between the two exposure periods against the average of CMR of the two periods (Fig. 4a) . The mean relative CMR difference (the horizontal unbroken line) was shifted a little below zero, but this was not statistically significant (Table 2) . One subject had high CMRs compared with the other subjects and a relatively large change in CMR (the dot furthest to the right).
The QMR data are presented in Fig. 4b . The mean relative QMR difference (the horizontal unbroken line) was shifted a little above zero, but this was not statistically significant (Table 2) . One subject (not the same as the one who had high CMRs above) had a relatively large change in quinidine metabolism.
The associations between the relative difference in CMR or QMR and serum miconazole concentrations are shown in Fig. 5 . A low, non-statistically significant decrease (p= 0.33) in relative CMR difference with increased concentration of miconazole in serum was indicated. There was no concentration-dependent association (p = 0.89) between QMR and miconazole. 
Discussion
In this study we demonstrated that the use of a vaginal suppository containing 1,200 mg miconazole resulted in a mean serum concentration of miconazole of 12.9±5.6 μg/L (n=20) after 34 -h use. No substantial mean differences in CYP1A2 and CYP3A4 activities were observed after exposure to miconazole (exposure range: 3.5-24.6 μg/L serum). However, a weak negative and statistically nonsignificant association between the serum concentrations of miconazole and the relative difference in CMR was seen, indicating inhibition of CYP1A2. Because of considerable interindividual variations in the metabolic ratios and in the absorbed miconazole concentration only marked effects on enzyme activities can be detected in this study. Post hoc calculations using the standard deviation obtained from this study show that a true relative difference of at least 0.2 could be demonstrated for both CMR (n=14) and QMR (n=19) activities at a significance level of 5% and with a power of 80%. The association should therefore be interpreted with caution.
The large variation in serum miconazole absorption between subjects is in accordance with a previous study (mean serum concentration: 10.4±4.2 μg/L, n=11) [3] . The reason for this variation is not clarified, but might be due to differences in the vaginal environment and physical activity. In our study, neither menstruation during the study nor the duration of vaginal miconazole leakage (subjective evaluation of vaginal discharge) seemed to influence the systemic concentration of miconazole. The subjects were not examined for vaginal infections, but a damaged mucous membrane could probably absorb more miconazole, similar to when slightly damaged skin increased the penetration of pesticides in an in vitro skin model [28] . Also, genetic variations in the biotransformation of miconazole might play a role [29] . Other formulations of vaginal miconazole, i.e. vaginal cream, are not expected to give higher or lower systemic levels as the application is repeated every day for 2 weeks, resulting in a similar total local dose to that with the suppository. The mean CMR (CYP1A2 activity) estimated before the exposure to miconazole was 4.3±1.5. This was very similar to the values obtained in two other studies with nonsmoking Caucasian women who did not use oral contraceptives [26, 30] . In a study with Faroese residents the overall mean (not adjusted for confounders such as gender, smoking, oral contraceptives) was 7.8±5.8 (n=307) [31] , which was statistically significantly different from a Danish twin study with a mean value of 5.9±3.4 (n=378) [30] , indicating that genetic or environmental factors or both should be considered when measuring and comparing CYP1A2 activity.
None of the women in our study used oral contraceptives or other medical products. All women were Caucasian except for one whose genetic background was unknown. This woman smoked occasionally and she was the only smoker included in the determination of CYP1A2 activity. No obvious deviation from the results of the other women was observed for this subject. Intraindividual variability may derive from difference in morning urine sampling time before and during miconazole exposure as the time interval differed by up to 4 h. It could also be speculated that the menstrual cycle might influence the activities of the enzymes and add to the variability, although studies investigating the effect of the menstrual cycle on CYP1A2 and CYP3A4 activities did not report such an effect [32] [33] [34] .
The mean CYP3A4 activity (based on QMR) was not affected by exposure to miconazole. The wide interindividual variability was in accordance with other studies determining CYP3A4 based on the urinary 6β-hydroxycortisol/cortisol ratio or formation clearance of 3-hydroxyquinidine [23, 35] . One woman had a decreased CYP3A4 activity during the use of the miconazole vaginal suppository, but it was not the woman with the highest concentration of absorbed miconazole. The cause has not been identified, as the subjects were instructed to refrain from known CYP3A4 inhibitors. Miconazole and quinidine are both known inhibitors of Pglycoprotein and also likely substrates for this efflux transporter [36] [37] [38] [39] . Intake of quinidine during miconazole exposure could be speculated to reduce the hepatic elimination of miconazole causing an elevation of the systemic concentration of miconazole. By inhibiting P-glycoprotein, miconazole use during pregnancy might also increase the placental transfer of other exogenous compounds that are Pglycoprotein substrates. In placenta, P-glycoprotein is expressed both at the membrane facing maternal circulation and at the membrane facing fetal circulation [40] . If not metabolised in the placenta, miconazole concentration may increase in this tissue when pregnant women are treated with miconazole.
Miconazole has been reported to inhibit several CYP enzymes in human liver or lymphoblast microsomes in vitro, including CYP1A2 and CYP3A4, with an inhibition constant (K i ) of 3.2 and 0.028 μM [14] and a half maximal inhibitory concentration (IC 50 ) of 2.9 and 0.074 μM [41, 42] respectively. This indicates that miconazole in the mean absorbed concentration of 12.9 μg/L serum corresponding to 0.03 μM might also have an effect on the enzymes in vivo.
Miconazole is used for treatment of vaginal mycoses, even in pregnant women, and of oral candidiasis in infants as these treatments are regarded as being effective and safe with regard to an alleged negligible absorption [2, 3] . The mean serum miconazole concentration of 12.9 μg/L was indeed low, but remained so for several days [3] . The biological effect measured in individuals using the miconazole-containing suppository was negligible. However, orally administered miconazole has been reported to interact with the CYP2C9 substrate warfarin in vivo [7, [43] [44] [45] . Hence, if miconazole is present with sufficient systemic concentration, a biological effect in vivo of miconazole is possible. Therefore, the potential adverse effects on the developing fetus and infant after miconazole exposure should be investigated further in vivo. Furthermore, it should be investigated whether miconazole is transferred to the fetus or if miconazole concentration is increased in the placenta with the possibility of disturbing the development of the fetus or the placental function respectively.
In conclusion, miconazole is absorbed via the vaginal mucosa to the systemic circulation in measurable concentrations. Our data indicate a concentration-dependent inhibition of CYP1A2, but the effect is negligible compared with the variation in the activity of CYP1A2 and is regarded to be of no clinical significance to the women. However, further studies on the ability of miconazole to be transferred across the placenta or to interfere with the placental function are warranted to ensure safe use during pregnancy.
